AB0700 GOLIMUMAB PERSISTENCE IN BIOLOGIC NAÏVE AND NON-NAÏVE PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS OF THE GO-PRACTICE STUDY

Autor: Florence Tubach, Jean Ouaniche, Bruno Fautrel, Philippe Bertin, Eric Lespessailles, Philippe Goupille, N Gouyette, Naoual Harid, René-Marc Flipo, Jean-Marie Fayette
Rok vydání: 2019
Předmět:
Zdroj: Abstracts accepted for Publication.
Popis: Background: Golimumab (GLM) was the latest anti-TNFα therapy to be indicated in the treatment of chronic inflammatory rheumatic diseases. The pivotal GO-AFTER study [1] and the ongoing observational GO-BEYOND study investigate GLM efficacy in rheumatoid arthritis (RA) patients who previously received biologics. However, clinical studies of GLM in axial spondyloarthritis (AS) are lacking. Using data from the GO-PRACTICE study, we examined GLM persistence in patients with aS. Objectives: Primary objective was to estimate GLM persistence at 2 years from initial prescription, as a first line of treatment (in biologic naive patients:BN) and as a second or further line of treatment (in biologic pretreated patients:BP). Persistence was estimated with the Kaplan-Meier method. Secondary outcomes included assessing disease activity (ASDAS) evolution and patient-reported evaluations of disease activity (BASDAI), pain (VAS), functional ability (HAQ) and quality of life (EQ-5D and SF-12). Methods: Observational, prospective, multicenter French study, that recruited adult patients with RA, psoriatic arthritis or aS, who were newly prescribed GLM. Patients were followed-up over 2 years; data were collected at baseline (BL), 1 year and 2 years. This abstract presents results from the aS cohort of GO-PRACTICE. Results: 478 patients with aS (constituting 63% of the total cohort) from 134 sites were included from January 2015 to March 2016. Mean age was 43 years, 55% were female; 61% were BN (n=291) and 39% (n=187) were BP. Mean duration of aS was 5.5 and 10.7 years in BN and BP patients, respectively (P Conclusion: GLM is associated with clinical improvements and good persistence in aS patients, especially those who are biologic naive. References [1] Smolen JS, et al; arthritis research & therapy2015,17:14 Disclosure of interests: Philippe Bertin Grant/research support from: Financial compensation received from MSD on a pro-rota basis for participation in Scientific Committee meetings and functions for this study, Philippe Goupille Grant/research support from: Financial compensation received from MSD on a pro-rota basis for participation in Scientific Committee meetings and functions for this study, Speakers bureau: abbvie, Biogaran, BMS, Hospira, Janssen, MSD, Pfizer, Sanofi-Genzyme, UCB, Florence Tubach Grant/research support from: Financial compensation received from MSD on a pro-rota basis for participation in Scientific Committee meetings and functions for this study, Jean OUANICHE Grant/research support from: Financial compensation received from MSD on a pro-rota basis for active participation in Scientific Committee meetings and functions, Eric Lespessailles Grant/research support from: Grants/research support from amgen, Eli Lily, MSD, UCB., Consultant for: Consultant for amgen, Expanscience, Eli Lilly, MSD, UCB., Najat Gouyette Employee of: MSD, France, Naoual HARID Employee of: MSD, France, jean-marie Fayette Consultant for: Contract Research Organisation - ClinSearch, Bruno Fautrel Grant/research support from: abbVie, Lilly, MSD, Pfizer, Consultant for: abbVie, Biogen, BMS, Celgene, Janssen, Lilly, Medac, MSD, NORDIC Pharma, Novartis, Pfizer, Roche, Sanofi-Aventis, Sanofi Genzyme, SOBI, UCB, Rene-Marc Flipo Consultant for: Honoraria from Novartis as steering committe of this survey
Databáze: OpenAIRE
Externí odkaz: